Diosmetin as a surrogate [Regulatives / Guidelines]

posted by Jana Zigova – Slovakia, 2015-02-10 10:34 (4156 d 17:55 ago) – Posting: # 14394
Views: 6,623

Dear forum members,

I would appreciate your opinion regarding following query:
Current EU guideline on BE discourages from the use of a metabolite as a surrogate for parent compound, pointing it can be accepted only exceptionally.
This might be the case of Diosmin products for which determination of Diosmin in human plasma is impossible. Even the determination of Diosmin’s aglicon – free Diosmetin – has proven to be difficult due to its low concentrations, for most of Diosmetin is present in the blood as glucuronide.
The solution might be represented by enzymatic degradation of plasma samples applied to conjugated Diosmetin.
I am just wondering whether this kind of surrogate – free Diosmetin obtained after enzymatic degradation – can be viewed as the acceptable one.

Looking forward to your view!

Jana

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
338 visitors (0 registered, 338 guests [including 12 identified bots]).
Forum time: 05:29 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5